drugset
drugset / Trial / NCT01005914

Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT01005914 ↗

Phase 2 Terminated 11 enrolled OHSU Knight Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects of giving pegaspargase together with combination chemotherapy and to see how well it works in treating patients with newly diagnosed acute lymphoblastic leukemia.

Timeline

Start
2009-06
Primary completion
2013-03
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegaspargase Protein / enzyme biologic 2500 iu Intravenous
Background Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Background Cytarabine Small molecule 3 g Intravenous
Background Dexamethasone Small molecule 40 mg Intravenous
Background Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Background Imatinib Small molecule 600 mg Oral
Background Methotrexate Small molecule 800 mg/m2 Intravenous
Background Methylprednisolone Other / unclassified 50 mg Intravenous
Background Vincristine Small molecule 2 mg Intravenous

Indications

leukemia